Table 3.
Cox proportional hazard model for overall survival
Variable | Reference | Univariate analysis |
Multivariate analysis |
||||
---|---|---|---|---|---|---|---|
Hazard ratio | 95% CI | p-value | Hazard ratio | 95% CI | p-value | ||
Age | |||||||
≥ 75 yr | < 75 yr | 0.62 | 0.31-1.23 | 0.172 | - | - | - |
Smoking history | |||||||
Former or current | Never | 0.66 | 0.46-0.96 | 0.028 | 0.65 | 0.44-0.94 | 0.024 |
Histology | |||||||
Squamous cell carcinoma | Adenocarcinoma | 0.92 | 0.62-1.38 | 0.697 | - | - | - |
Brain metastasis | |||||||
Yes | No | 1.40 | 0.93-2.11 | 0.110 | - | - | - |
Liver metastasis | |||||||
Yes | No | 2.38 | 1.52-3.75 | < 0.001 | 2.18 | 1.37-3.47 | 0.001 |
ECOG PS | |||||||
2 | 0-1 | 1.60 | 0.97-2.65 | 0.067 | - | - | - |
Previous treatment line | |||||||
≥ 2 | 1 | 1.42 | 0.94-2.15 | 0.094 | - | - | - |
Immune-related AE | |||||||
Yes | No | 0.44 | 0.29-0.67 | < 0.001 | 0.50 | 0.33-0.76 | 0.001 |
AE | |||||||
Yes | No | 0.77 | 0.44-1.35 | 0.360 | - | - | - |
EGFR | |||||||
Positive | Negative | 0.94 | 0.52-1.72 | 0.854 | - | - | - |
CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; AE, adverse effect; EGFR, epidermal growth factor receptor.